Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
AZD4877 · 3 trials · 9 indications
Percentage of participants with complete response (CR) or partial response (PR) as per Response Evaluation Criteria In Solid Tumors (RECIST), version 1.0 (Therasse et al. Natl Cancer Inst 92 (2000) pp205-216).
| Arm | Type | Description |
|---|---|---|
| AZD4877 | EXPERIMENTAL | Single agent AZD4877 |
| Name | Type | Description |
|---|---|---|
| AZD4877 | DRUG | Intravenous (IV)25mg/weekly |
Inclusion Criteria: * Confirmed urothelial cancer (cancer of the bladder, renal pelvis, ureter, or urethra). * Tumor, Node, Metastasis (TNM) Stage IV urothelial cancer that can not be helped by curative surgery and/or curative radiotherapy * Must have had a maximum of 2 prior chemotherapeutic regim...
Top 20 of 51 competitors
AZD4877 is an investigational small molecule developed by AstraZeneca PLC (ticker AZN) for the treatment of cancer. It has been studied in solid tumors and advanced bladder cancer, including transitional cell bladder cancer and cancers of the urethra, ureter, and renal pelvis. It is not an approved therapy and remains in clinical development.
AZD4877 was studied in a Phase 2 trial in advanced bladder cancer, including transitional cell bladder cancer and cancers of the urethra, ureter, and renal pelvis. That study, NCT00661609, enrolled 54 patients across the United States, Canada, Germany, Spain, and the United Kingdom and has been completed.
AZD4877 targets KIF11, a kinesin motor protein, and acts as an inhibitor of that target. KIF11 inhibition interferes with mitotic spindle function, which is why AZD4877 is described as an anti-mitotic agent. This mechanism is what supports its investigation in solid tumors and bladder cancer.
AZD4877 is developed by AstraZeneca PLC, which trades under the ticker AZN. AstraZeneca sponsored the clinical program for the drug, including the Phase 2 bladder cancer study and the Phase 1 solid tumor and Japanese dose-escalation studies.
AZD4877 reached Phase 2 in its clinical development. It is an investigational agent and is not an approved medicine. The Phase 2 study in advanced bladder cancer has been completed, and no trials of AZD4877 are currently active.
AZD4877 has been evaluated in three completed trials: NCT00661609, a Phase 2 study in advanced bladder cancer with 54 patients; NCT00613652, a Phase 1 dose-escalation study in Japanese adults with cancer; and NCT00389389, a Phase 1 dose-escalation study in solid tumors with 75 patients.